Reslizumab
Cinqair, Cinqaero (reslizumab) is an antibody pharmaceutical. Reslizumab was first approved as Cinqair on 2016-03-23. It is used to treat asthma in the USA. It has been approved in Europe to treat asthma. The pharmaceutical is active against interleukin-5.
| Trade Name | Cinqaero |
|---|---|
| Common Name | Reslizumab |
| Indication | asthma |
| Drug Class | Monoclonal antibodies: humanized, immunomodulating |
